ABINs inhibit EGF receptor-mediated NF-κB activation and growth of EGF receptor-overexpressing tumour cells

Oncogene

Volumn 27, Issue 47, 2008, Pages 6131-6140

  Huang, L ^a,b,c   Verstrepen, L ^b,c   Heyninck, K ^b,c   Wullaert, A ^b,c   Revets, H ^a,b   De Baetselier, P ^a,b   Beyaert, R ^b,c  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

ABIN; Cancer; EGF receptor; NF B; Proliferation

Indexed keywords

ABIN 1 PROTEIN; ABIN 2 PROTEIN; CELL PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; I KAPPA B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; PROTEIN P100; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADENOVIRUS; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CARCINOMA CELL; CELL PROLIFERATION; COMPETITIVE INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TUMOR CELL; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DNA-BINDING PROTEINS; EPIDERMAL GROWTH FACTOR; GENE THERAPY; HUMANS; I-KAPPA B PROTEINS; NEOPLASMS; NF-KAPPA B; NF-KAPPA B P52 SUBUNIT; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 54049109210     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.208     Document Type: Article

References (64)

1. Adli M, Baldwin AS. (2006). IKK-i/IKKε controls constitutive, cancer cell-associated NF-κB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem 281: 26976-26984.
2. Anest V, Cogswell PC, Baldwin AS. (2004). IκB kinase a and p65/RelA contribute to optimal epidermal growth factor-induced c-fos gene expression independent of IκBα degradation. J Biol Chem 279: 31183-31189.
3. Anto RJ, Venkatraman M, Karunagaran D. (2003). Inhibition of NF-κB sensitizes A431 cells to epidermal growth factor-induced apoptosis, whereas its activation by ectopic expression of RelA confers resistance. J Biol Chem 278: 25490-25498.
4. Bhat-Nakshatri P, Sweeney CJ, Nakshatri H. (2002). Identification of signal transduction pathways involved in constitutive NF-κB activation in breast cancer cells. Oncogene 21: 2066-2078.
5. Biswas DK, Cruz AP, Gansberger E, Pardee AB. (2000). Epidermal growth factor-induced nuclear factor κB activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 97: 8542-8547.
6. Biswas DK, Dai SC, Cruz A, Weiser B, Graner E, Pardee AB et al. (2001). The nuclear factor κ B (NF-κB): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci USA 98: 10386-10391.
7. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB et al. (2004). NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101: 10137-10142.
8. Buss H, Dorrie A, Schmitz ML, Hoffmann E, Resch K, Kracht M et al. (2004). Constitutive and interleukin-1-inducible phosphorylation of p65 NF-κB at serine 536 is mediated by multiple protein kinases including IκB kinase (IKK)-α, IKKβ, IKKε, TRAF family member-associated (TANK)-binding kinase 1. J Biol Chem 279: 55633-55643.
9. Carter RE, Sorkin A. (1998). Endocytosis of functional epidermal growth factor receptor-green fluorescent protein chimera. J Biol Chem 273: 35000-35007.
10. Chen D, Xu LG, Chen L, Li L, Zhai Z, Shu HB et al. (2003). NIK is a component of the EGF/heregulin receptor signaling complexes. Oncogene 22: 4348-4355.
11. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA et al. (2005). Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65: 3328-3335.
12. Damiano V, Caputo R, Bianco R, D0Armiento FP, Leonardi A, De Placido S et al. (2006). Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 12: 577-583.
13. De Valck D, Heyninck K, Van Criekinge W, Vandenabeele P, Fiers W, Beyaert R (1997). A20 inhibits NF-κB activation independently of binding to 14-3-3 proteins. Biochem Biophys Res Commun 238: 590-594.
14. El Bakkouri K, Wullaert A, Haegman M, Heyninck K, Beyaert R. (2005). Adenoviral gene transfer of the NF-κB inhibitory protein ABIN-1 decreases allergic airway inflammation in a murine asthma model. J Biol Chem 280: 17938-17944.
15. El Sheikh SS, Domin J, Abel P, Stamp G, Lalani E-N. (2004). Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 6: 846-853.
16. Fan Z, Masui H, Altas I, Mendelsohn J. (1993). Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53: 4322-4328.
17. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ et al. (2002). The role of IKK in constitutive activation of NF-κB transcription factor in prostate carcinoma cells. J Cell Sci 115: 141-151.
18. Grempler R, Kienitz A, Werner T, Meyer M, Barthel A, Ailett F et al. (2004). Tumour necrosis factor α decreases glucose-6-phosphatase gene expression by activation of nuclear factor κB. Biochem J 382: 471-479.
19. Guo G, Wang T, Gao Q, Tamae D, Wong P, Chen T et al. (2004). Expression of ErbB2 enhances radiation-induced NF-κB activation. Oncogene 23: 535-545.
20. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin Jr AS. (1999). NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19: 5785-5799.
21. Hacker H, Karin M. (2006). Regulation and function of IKK and IKK-related kinases. Sci STKE 2006: re13.
22. Häussler U, von Wichert G, Schmid RM, Keller F, Schneider G. (2005). Epidermal growth factor (EGF) activates nuclear factor κB in human proximal tubule cells. Am J Physiol Renal Physiol 289: F808-F815.
23. Heyninck K, Beyaert R. (2005). A20 inhibits NF-κB activation by dual ubiquitin-editing functions. Trends Biochem Sci 30: 1-4.
24. Heyninck K, De Valck D, Vanden Berghe W, Van Criekinge W, Contreras R, Fiers W et al. (1999). The zinc finger protein A20 inhibits TNF-induced NF-κB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-κB-inhibiting protein ABIN. J Cell Biol 145: 1471-1482.
25. Heyninck K, Kreike MM, Beyaert R. (2003). Structure-function analysis of the A20-binding inhibitor of NF-κB activation, ABIN-1. FEBS Lett 536: 135-140.
26. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M et al. (1999). NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19: 2690-2698.
27. Hoeller D, Crosetto N, Blagoev B, Raiborg C, Tikkanen R, Wagner S et al. (2006). Regulation of ubiquitin-binding proteins by mono-ubiquitination. Nat Cell Biol 8: 163-169.
28. Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H et al. (2006). Targeting the EGFR pathway for cancer therapy. Curr Med Chem 13: 3483-3492.
29. Keutgens A, Robert I, Viatour P, Chariot A. (2006). Deregulated NF-κB activity in haematological malignancies. Biochem Pharmacol 72: 1069-1080.
30. Konger RL, Chan TC. (1993). Epidermal growth factor induces terminal differentiation in human epidermoid carcinoma cells. J Cell Physiol 156: 515-521.
31. Le Page C, Koumakpayi IH, Lessard L, Saad F, Mes-Masson A-M. (2005). Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-κB activation in prostate cancer cells. Prostate 65: 306-315.
32. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM et al. (2003). Mitogenic and antiapoptotic role of constitutive NF-κB/ Rel activity in pancreatic cancer. Int J Cancer 105: 735-746.
33. Makino K, Day C-P, Wang S-C, Li YM, Hung M-C. (2004). Upregulation of IKKα/IKKbeta by integrin-linked kinase is required for HER2/neu-induced NF-κB antiapoptotic pathway. Oncogene 23: 3883-3887.
34. Mauro C, Pacifico F, Lavorgna A, Mellone S, Iannetti A, Acquaviva R et al. (2006). ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-κB. J Biol Chem 281: 18482-18488.
35. Meeran SM, Katiyar SK. (2008). Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front Biosci 13: 2191-2202.
36. Miggin SM, O'Neill LAJ. (2006). New insights into the regulation of TLR signaling. J Leukoc Biol 80: 220-226.
37. Neumann M, Naumann M. (2007). Beyond IκBs: alternative regulation of NF-κB activity. FASEB J 21: 2642-2654.
38. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR et al. (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16.
39. Olivier S, Robe P, Bours V. (2006). Can NF-κB be a target for novel and efficient anti-cancer agents? Biochem Pharmacol 72: 1054-1068.
40. Pacifico F, Leonardi A. (2006). NF-κB in solid tumors. Biochem Pharmacol 72: 1142-1152.
41. Papoutsopoulou S, Symons A, Tharmalingham T, Belich MP, Kaiser F, Kioussis D et al. (2006). ABIN-2 is required for optimal activation of Erk MAP kinase in innate immune responses. Nat Immunol 7: 606-615.
42. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J et al. (1996). Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 56: 3666-3669.
43. Reid A, Vidal L, Shaw H, de Bono J. (2007). Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43: 481-489.
44. Romashkova JA, Makarov SS. (1999). NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401: 86-90.
45. Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB, Chiao PJ et al. (2003). Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-κB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg 7: 37-43; discussion 43.
46. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB. (2007). Epidermal growth factor (EGF) activates nuclear factor-κB through IκBα kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IκBα. Oncogene 26: 7324-7332.
47. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD et al. (2007). Nuclear factor-κB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 6: 1973-1982.
48. Sitcheran R, Gupta P, Fisher PB, Baldwin AS. (2005). Positive and negative regulation of EAAT2 by NF-κB: a role for N-myc in TNFα-controlled repression. EMBO J 24: 510-520.
49. Stover DR, Becker M, Liebetanz J, Lydon NB. (1995). Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85α. J Biol Chem 270: 15591-15597.
50. Strassheim D, Asehnoune K, Park J-S, Kim J-Y, He Q, Richter D et al. (2004). Phosphoinositide 3-kinase and Akt occupy central roles in inflammatory responses of Toll-like receptor 2-stimulated neutrophils. J Immunol 172: 5727-5733.
51. Sun L, Carpenter G. (1998). Epidermal growth factor activation of NF-κB is mediated through IκBα degradation and intracellular free calcium. Oncogene 16: 2095-2102.
52. Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ et al. (2006). Nuclear factor-κB (NF-κB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 107: 2637-2646.
53. Tian B, Nowak DE, Jamaluddin M, Wang S, Brasier AR. (2005). Identification of direct genomic targets downstream of the nuclear factor-κB transcription factor mediating tumor necrosis factor signaling. J Biol Chem 280: 17435-17448.
54. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA et al. (1995). Phosphorylation of human IκB-α on serines 32 and 36 controls IκB-α proteolysis and NF-κ B activation in response to diverse stimuli. EMBO J 14: 2876-2883.
55. Van Huffel S, Delaei F, Heyninck K, De Valck D, Beyaert R. (2001). Identification of a novel A20-binding inhibitor of nuclear factor-κB activation termed ABIN-2. J Biol Chem 276: 30216-30223.
56. Van Laere SJ, Van der Auwera I, Van den Eynden GG, van Dam P, Van Marck EA, Vermeulen PB et al. (2007). NF-κB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br J Cancer 97: 659-669.
57. Verstrepen L, Adib-Conquy M, Kreike M, Carpentier I, Adrie C, Cavaillon J-M et al. (2008). Expression of the NF-κB inhibitor ABIN-3 in response to TNF and toll-like receptor 4 stimulation is itself regulated by NF-κB. J Cell Mol Med 12: 316-329.
58. Wagner S, Carpentier I, Rogov V, Kreike M, Ikeda F, Lohr F et al. (2008). Ubiquitin binding mediates the NF-κB inhibitory potential of ABIN proteins. Oncogene 27: 3739-3759.
59. Weaver BK, Bohn E, Judd BA, Gil MP, Schreiber RD. (2007). ABIN-3: a molecular basis for species divergence in interleukin-10-induced anti-inflammatory actions. Mol Cell Biol 27: 4603-4616.
60. Wullaert A, Heyninck K, Janssens S, Beyaert R. (2006). Ubiquitin: tool and target for intracellular NF-κB inhibitors. Trends Immunol 27: 533-540.
61. Wullaert A, Verstrepen L, Van Huffel S, Adib-Conquy M, Cornelis S, Kreike M et al. (2007). LIND/ABIN-3 is a novel lipopolysaccharide-inducible inhibitor of NF-κB activation. J Biol Chem 282: 81-90.
62. Wullaert A, Wielockx B, Van Huffel S, Bogaert V, De Geest B, Papeleu P et al. (2005). Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality. Hepatology 42: 381-389.
63. Yang C, Klein EA, Assoian RK, Kazanietz MG. (2008). Heregulin beta1 promotes breast cancer cell proliferation through Rac/Erk-dependent Induction of cyclin D1 and p21 Cip1. Biochem J 410: 167-175.
64. Zhang S, Fukushi M, Hashimoto S, Gao C, Huang L, Fukuyo Y et al. (2002). A new ERK2 binding protein, Naf1, attenuates the EGF/ERK2 nuclear signaling. Biochem Biophys Res Commun 297: 17-23.